For many patients with diverse and seemingly unrelated symptoms, obtaining an accurate diagnosis can take years of specialist visits and inconclusive tests. Mast cell activation syndrome, a disorder ...
Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback